BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Happy 40th Birthday, Louise Brown, the World’s First IVF Baby

  Forty years ago, Louise Brown was born on July 25. She was the first so-called “test tube baby,” born through in vitro fertilization (IVF).

  July 26, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Bristol-Myers Squibb Reports 11% Increase in Total Revenues for Q2

  Bristol-Myers Squibb reported a strong second quarter, with total revenues of $5.7 billion, up 11 percent from the same quarter in 2017, when it reported $5.144 billion. Sales were driven by Eliquis (apixaban) and Opdivo (nivolumab).

  July 26, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  Roche Quarterly Financials: “Firing on All Cylinders”

  Roche announced a strong second quarterly report with a 7 percent increase in group sales for the first half of the year and a 20 percent increase in its core earnings per share (EPS).

  July 26, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  3 Biotech Stocks That Might Double Your Money in the Short Term

  Although the overall stock market has been a bit jittery as the result of a trade war, biotech stocks have been surprisingly steady—at least in comparison to their usual volatility.

  July 26, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  AstraZeneca’s Cancer Drugs Mostly Soar With One Bomb Amidst Quarterly Report

  AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On the bad news side, the company’s selumetinib failed another clinical trial.

  July 26, 2018

   · 

  2 min read

   · 

  Mark Terry
• 

  Drug Development

  Biogen Investors Underwhelmed by Alzheimer’s Study Update

  It’s hard to say if it was actually a wild ride after the release of Alzheimer’s data, but Biogen shares dropped from $383.83 to $340.84 at the news, although it appears to be rebounding slightly.

  July 26, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Achaogen to Cut 80 Jobs as Part of Corporate Restructuring

  Achaogen, headquartered in South San Francisco, announced that as part of its strategic update and corporate restructuring, it will eliminate 80 positions, or about 28 percent of staff.

  July 26, 2018

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Genentech, Horizon Earn Spots on List of ‘Companies That Care’

  Genentech and Horizon Pharma were the only two biopharma companies that made People’s 2018 list of “50 Companies That Care,” a list that highlights how a company makes a difference in the lives of its employees, as well as the communities those companies call home.

  July 26, 2018

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Novartis Taps Shyft Analytics To Drive Company’s Digital Transformation

  Before taking over the helm of Novartis AG, Vasant Narasimhan pointed to the harnessing of digital technology as a key method of saving a significant percentage of clinical trial costs.

  July 26, 2018

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Biogen’s Q2 Report Gets Investors Excited Again

  Many analysts and investors were holding their breaths, waiting to see what Biogen would say at yesterday’s second-quarter financial report. The financials weren’t the focus, however, but what the Cambridge, Massachusetts biotech had to say about its pipeline, especially for Alzheimer’s disease, was.

  July 26, 2018

   · 

  3 min read

   · 

  Mark Terry